Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

ASX 200 To Open Lower, 3 ASX Shares To Watch

The ASX 200 (INDEXASX:XJO)(^AXJO) is expected to open lower today, the USA’s S&P 500 Index (.INX) went down by 0.04% on Thursday.
ASX news Nick Scali

The ASX 200 (INDEXASX: XJO)(^AXJO) is expected to open lower today, the USA’s S&P 500 Index (.INX) went down by 0.04% on Thursday.

Australian Dollar ($A) (AUDUSD): 70.17US cents

Dow Jones (DJI): down 0.51%

Oil (WTI): $US65.11 per barrel

Gold: $US1,278 per ounce

ASX Sharemarket News

In ASX sharemarket news, Flight Centre Travel Group Ltd (ASX: FLT) may see its share price come under pressure today with the travel business issuing a profit guidance downgrade.

The company said that its Australian leisure results have not recovered because of subdued trading conditions which is impacting total transaction value (TTV) measures.

Flight Centre also named a few other internal reasons for a decrease of profit.

Overall, the company is now expecting underlying profit before tax (PBT) for FY19 to be between $335 million to $360 million, which is below the $390 million to $420 million range previously guided. The mid-point of the new range, $347.5 million, would be a 10% decrease on FY18’s result.

[ls_content_block id=”15758″ para=”paragraphs”]

Real estate giant Unibail-Rodamco-Westfield (ASX: URW) has revealed its March 2019 figures.

Tenant sales in its European shopping centres increased by 4.3% and footfall increased by 2.4%. US specialty sales per square foot grew by 5.3%. The business’ proportionate revenue increased by 70.2% to €939.6 million, largely due to the Westfield acquisition.

Since 7 June 2018 it has made €3.1 billion of disposals with an average premium above book value of 7.2%. In other words, it managed to sell assets at a higher price than what they were listed on the balance sheet for.

Popular Stories:

Biopharmaceutical business  Telix Pharmaceuticals Ltd (ASX: TLX) has published its fractionated prostate cancer therapy data with the results reportedly showing significant treatment benefit to patients.

The announcement said that a significant anti-tumour response is observed, particularly at the higher dosing levels.

[ls_content_block id=”18457″ para=”paragraphs”]

[ls_content_block id=”18380″ para=”paragraphs”]

Skip to content